The U.S. Federal Trade Commission (FTC) has settled with two makers of ultraviolet light devices that the agency said made false claims about product efficacy. The devices were marketed to consumers with claims that they could eliminate fungus and dangerous bacteria without providing sufficient supporting evidence, the agency said.
Amgen has already paid $762 million to wrap up off-label marketing claims with the feds. Now, 48 states have won another promise to pay from the California-based drugmaker. This time, it's $71 million to resolve allegations that it broke the rules when marketing its anemia drug Aranesp and anti-inflammatory blockbuster Enbrel, two of its best-selling meds.
C.R. Bard has settled 3,000 cases by women injured from its vaginal mesh for more than $200 million. This is the latest in a parade of large settlements in recent months over the implants, which are said to cause pain and internal damage, from the likes of Endo International, Medtronic, Boston Scientific and Johnson & Johnson.
Takeda Pharmaceutical is about to make history that it would prefer not to make. When it produces its quarterly report for the fiscal year that ended March 31, it is expected to post its first net loss since it first listed on the Tokyo Stock Exchange in 1949.
Johnson & Johnson lost another battle in its ongoing vaginal mesh litigation, as a California jury ordered the company to pay $5.6 million in the first trial over one of its mesh devices.
In mid-January, Johnson & Johnson asked the district judge overseeing the federal lawsuit over the transvaginal mesh devices from its Ethicon subsidiary to investigate phone calls urging women with the implant to file suit against the company. But now it's requesting to withdraw that motion.
Medtronic has reached a $22 million settlement with 950 claimants over liability claims related to Infuse Bone Graft. The company denied any wrongdoing and said it will continue to "vigorously defend" the product in remaining cases.
In PatientView's annual survey of patient groups around the world, survey respondents gave a thumbs-up to drugmakers' innovation and quality. They weren't as impressed, however, with pharma marketing.
After investigating Teva Pharmaceutical Industries for potential bribery overseas in 2012, U.S. prosecutors have turned to Teva's marketing, eyeing two branded medications, its top-selling multiple sclerosis drug Copaxone and its Parkinson's disease treatment Azilect.
Johnson & Johnson has been negotiating terms of a multibillion dollar settlement over aggressive marketing of its antipsychotic drug Risperdal with federal authorities for at least two years, and now it is hung on talk over breasts, The Wall Street Journal says.